Details for Patent: 10,456,384

Which drugs does patent 10,456,384 protect, and when does it expire?

Patent 10,456,384 protects XIFAXAN and is included in one NDA.

This patent has thirty patent family members in fifteen countries.

Summary for Patent: 10,456,384

Title:	Methods for treating irritable bowel syndrome (IBS)
Abstract:	The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.
Inventor(s):	Forbes; William (Raleigh, NC), Bortey; Enoch (Chapel Hill, NC)
Assignee:	Salix Pharmaceuticals, Inc. (Bridgewater, NJ)
Application Number:	15/902,179
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,456,384
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,456,384

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes						TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes						TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER

International Family Members for US Patent 10,456,384

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009219240
Australia	2010292043
Brazil	112012005627